- Home
- MSD vs MCRB Comparison
MSD vs MCRB Comparison
Compare MSD & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MSD | MCRB |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 139.7M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | MSD | MCRB |
|---|---|---|
| Price | $7.93 | $8.28 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 70.2K | ★ 95.3K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $351,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.68 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.11 | $6.53 |
| 52 Week High | $7.46 | $29.98 |
Technical Indicators
Market Signals| Indicator | MSD | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 86.44 | 22.76 |
| Support Level | $7.83 | $8.00 |
| Resistance Level | $7.90 | $14.69 |
| Average True Range (ATR) | 0.05 | 1.11 |
| MACD | 0.02 | -0.71 |
| Stochastic Oscillator | 100.00 | 3.27 |
Price Performance
Historical ComparisonAbout MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.